EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Risk factors for adverse drug reactions to sulfamethoxazole-trimethoprim prophylaxis in patients with rheumatic and musculoskeletal diseases

Kazuoto Hiramoto iD, Mitsuhiro Akiyama, Yuko Kaneko

Modern Rheumatology · 2024

DOI: 10.1093/mr/roae059 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Rheumatology, 2024. Verfasst von Kazuoto Hiramoto und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Musculoskeletal Diseases, Rheumatic Diseases, Trimethoprim, Sulfamethoxazole Drug Combination. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Risk factors for adverse drug reactions (ADRs) associated with prophylactic sulfamethoxazole-trimethoprim (SMX/TMP) in patients with rheumatic and musculoskeletal diseases undergoing immunosuppressive therapy remain unclear; we aimed to identify the risk factors associated with ADRs.

Methods

Consecutive patients with rheumatic and musculoskeletal diseases, who were admitted to Keio University Hospital and received prophylactic administration of SMX/TMP, were included. Data regarding ADRs to SMX/TMP were collected to identify the associated risk factors using multivariable analysis.

Results

Of 438 patients included in the analysis, 82 (18.7%) experienced ADRs. Patients in the ADR group were significantly older, had chronic kidney disease, and exhibited lower lymphocyte and platelet counts, lower albumin levels, lower estimated glomerular filtration rates, higher aspartate aminotransferase levels, and higher ferritin levels than those in the non-ADR group. Regarding the underlying rheumatic and musculoskeletal diseases, adult-onset Still’s disease (ASD) was associated with a significantly higher incidence of ADRs (67%) than other diseases. Multivariable analysis identified the presence of ASD and low lymphocyte counts as independent risk factors for allergic ADRs and older age and use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers for nonallergic ADRs.

Conclusions

Risk factors for ADRs associated with prophylactic SMX/TMP treatment in patients with rheumatic and musculoskeletal diseases were identified.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Musculoskeletal DiseasesRheumatic DiseasesTrimethoprim, Sulfamethoxazole Drug CombinationHumansMaleFemaleMiddle AgedRisk FactorsAgedAdultDrug-Related Side Effects and Adverse ReactionsAntibiotic Prophylaxis

Stichwörter der Autor:innen

Adult-onset Still’s diseaseadverse drug reactionsallergyrheumatic and musculoskeletal diseasesulfamethoxazole-trimethoprim

Substanzen

Trimethoprim, Sulfamethoxazole Drug Combination

Autor:innen und Institutionen

  • Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.

ORCID-Profile: Kazuoto Hiramoto

Zitieren

APA

Hiramoto, K., Akiyama, M., & Kaneko, Y. (2024). Risk factors for adverse drug reactions to sulfamethoxazole-trimethoprim prophylaxis in patients with rheumatic and musculoskeletal diseases. Modern Rheumatology. https://doi.org/10.1093/mr/roae059

Vancouver

Hiramoto K, Akiyama M, Kaneko Y. Risk factors for adverse drug reactions to sulfamethoxazole-trimethoprim prophylaxis in patients with rheumatic and musculoskeletal diseases. Modern Rheumatology. 2024. doi:10.1093/mr/roae059

BibTeX
@article{Hiramoto2024,
  author = {Hiramoto, Kazuoto and Akiyama, Mitsuhiro and Kaneko, Yuko},
  title = {Risk factors for adverse drug reactions to sulfamethoxazole-trimethoprim prophylaxis in patients with rheumatic and musculoskeletal diseases},
  journal = {Modern Rheumatology},
  year = {2024},
  doi = {10.1093/mr/roae059}
}
Kostenlos starten →